Your session is about to expire
← Back to Search
PF-07260437 for Solid Tumors (C4431001 Trial)
C4431001 Trial Summary
This trial is testing a new cancer treatment targeting B7-H4 expressing tumors. The safety and effectiveness of the treatment will be evaluated in adults with advanced breast, ovarian, or endometrial cancer.
- Breast Cancer
- Ovarian Tumors
- Endometrial Cancer
C4431001 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.C4431001 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have histological diagnosis of locally advanced or metastatic triple negative breast cancer with high B7-H4 expression.You have histological/cytological diagnosis of breast cancer, endometrial cancer or ovarian cancer.
- Group 1: Monotherapy dose escalation (Part 1)
- Group 2: Dose Expansion (Part 2B) - Tumor specific Arm B
- Group 3: Dose Expansion (Part 2A) - Tumor specific Arm A
- Group 4: Dose Expansion (Part 2C) - Tumor specific Arm C
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is PF-07260437 a reliable and secure treatment option for individuals?
"In view of the Phase 1 nature of this trial, there is little information on PF-07260437's efficacy and safety. As such, our assessment gave it a score of 1."
Are any openings currently available for participants in this trial?
"Affirmative. The records found on clinicaltrials.gov demonstrate that recruitment for this medical study, which was launched on October 7th 2021, is still in progress. In total, 14 different sites are looking to gather 100 participants into the trial."
Are there any Canadian medical centers participating in this investigation?
"This medical trial is recruiting patients at many different sites, such as Seattle Cancer Care Alliance in Washington, Moffitt Cancer Center at McKinley Campus in Florida and University of Chicago Medical Centre in Illinois. Others include 14 additional locations across the nation."
Approximately how many participants are participating in this research?
"To meet the necessary trial requirements, Pfizer needs to enroll 100 eligible participants across two sites: Seattle Cancer Care Alliance in Washington and Moffitt Cancer Center at McKinley Campus in Florida."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger